Table 3.
Thrombosis risk factors and associated outcomes
| Article (year) | Demographics | Risk factors for thrombosis | Anticoagulant therapy | Stent outcomes | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of study participants | Age, mean (years) | Female to male ratio | Hypercoagulable testing | Transient provoking factor | Chronic provoking factor | Unknown | Anticoagulant | INR goal | Duration (months) | Off A/C at 6 months | Time to occlusion in by 12 months | # Patients with occlusion or VTE recurrence within 12 months | |
| Goldman (2017) | 6 | 17 | 3:3 | 4/6 hypercoagulable testing positiveb | 2 | 0 | 4 | Variable but described (Fondaparinux, Enoxaparin, Warfarin) | Variable but delineated (6—lifelong) | 1/6 | 1, 11 | 2 | |
| Husman (2007) | 11 | 34 | 9:2 | Not identified | 11 | Warfarin | 2‐3 | 6 | Yes | 0.25 and 3 | 2 | ||
| Kim (2017) | 25 | 61 | 19:5 | Not identifieda | 11 | 14 | Warfarin | 2‐3 | 6 | Yes | 1 | ||
| Matsuda (2014) | 13 | 63 | 7:6 | 2/13 hypercoagulable testing positiveb | 6 | 6 | 1 | Warfarin | 1.5‐2.5 | Variable but delineated (6—lifelong) | 1/13 | 0.5 and 1 | 2 |
| Roy (2017) | 6 | 48 | 5:1b | Tested, but none identified | 1b | 5 | Warfarin | 2‐3 | “Long‐term” | N | 0 | ||
A/C, anticoagulation; DVT, deep vein thrombosis; INR, international normalized ratio; VTE, venous thromboembolism.
One patient with recurrence diagnosed with antiphospholipid antibody syndrome.
“Patients with hematologic disorders affecting the coagulation cascade” were excluded but these disorders were not defined.
One patient with recurrence was diagnosed with protein C deficiency.
It is unclear the genders of the six patients who underwent stent placement in the Roy study. Seven patients identified, (six female, one male), but one did not have stent placement, unclear which gender. That patient not included in this systematic review.
Patient recovering from a traumatic subdural hematoma requiring surgical intervention and rehabilitative services when DVT developed.